Long noncoding RNAs (lncRNAs) are a relatively well‐characterized class of noncoding
RNA (ncRNA) molecules, involved in the regulation of various cell processes, including …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Long non-coding RNAs (lncRNAs) comprise a diverse class of RNA transcripts> 200
nucleotides in length with limited protein-coding potential. In addition to their possible role in …

Prostate cancer (PCa) is the second most common cancer in men worldwide. A large
proportion of PCa are latent, never destined to progress or affect the patients' life. It is of …

Prostate specific antigen (PSA) remains the most used biomarker in the management of
early prostate cancer (PCa), in spite of the problems related to false positive results and …

Non-coding RNAs have long been associated with cancer development and progression,
and since their earliest discovery, their clinical potential in identifying and characterizing the …

This review discusses the most recent evidence for currently available risk stratification tools
in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic …

Abstract Prostate cancer antigen 3 (PCA3) is an overexpressed prostate long non-coding
RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome …

Triple-negative breast cancer (TNBC) patients usually lead to poor prognosis and survival
because of metastasis. The major sites for TNBC metastasis include the lungs, brain, liver …

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading
reason of death. Age, ethnicity, family history, and genetic defects are major factors that …